Abstract
Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.
| Original language | English |
|---|---|
| Pages (from-to) | 616-623 |
| Number of pages | 8 |
| Journal | Cephalalgia |
| Volume | 34 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- CGRP receptor antagonist
- hyperalgesia
- migraine
- Nitroglycerin
ASJC Scopus subject areas
- Clinical Neurology
Cite this
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. / Greco, R.; Mangione, A. S.; Siani, F.; Blandini, F.; Vairetti, M.; Nappi, G.; Sandrini, G.; Buzzi, M. G.; Tassorelli, C.
In: Cephalalgia, Vol. 34, No. 8, 2014, p. 616-623.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia
AU - Greco, R.
AU - Mangione, A. S.
AU - Siani, F.
AU - Blandini, F.
AU - Vairetti, M.
AU - Nappi, G.
AU - Sandrini, G.
AU - Buzzi, M. G.
AU - Tassorelli, C.
PY - 2014
Y1 - 2014
N2 - Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.
AB - Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.
KW - CGRP receptor antagonist
KW - hyperalgesia
KW - migraine
KW - Nitroglycerin
UR - http://www.scopus.com/inward/record.url?scp=84902588420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902588420&partnerID=8YFLogxK
U2 - 10.1177/0333102413517776
DO - 10.1177/0333102413517776
M3 - Article
AN - SCOPUS:84902588420
VL - 34
SP - 616
EP - 623
JO - Cephalalgia
JF - Cephalalgia
SN - 0333-1024
IS - 8
ER -